The Lung Cancer Study Group (LCSG) randomized 141 patients with resected stage II and III adenocarcinoma and large cell undifferentiated carcinoma to receive postoperative combined chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy or bacillus Calmette-Guerin (BCG) [BCG] and levamisole). One hundred forty-one patients were randomized into this study, with a mean time since randomization of 7.5 years and a mean observation period of 2.4 years.
The Lung Cancer Study Group (LCSG) randomized 141 patients with resected stage II and III adenocarcinoma and large cell undifferentiated carcinoma to receive postoperative combined chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy or bacillus Calmette-Guerin (BCG) and levamisole immumotherapy. Careful intraoperative staging was performed on all patients. Before randomization, patients were stratified by stage, weight loss, cardiac arrhythmia, and institution. Prognostic variables such as stage, age, weight loss, and nodal involvement were equally distributed between the two groups. Diseasefree survival was significantly prolonged in the group receiving chemotherapy. There was no evidence of a deleterious effect of the immunotherapy. This study indicates that postoperative CAP chemotherapy is effective in prolonging disease-free survival in these patients.
Five-year survival rates after surgery for stage III adenocarcinoma and large cell undifferentiated carcinoma range between 8 and 15%, with median disease-free survival of 6 to 7 months.' 4 In 50 to 75% of the patients, the first site of recurrence is systemic. Previous studies evaluating adjuvant chemotherapy with a variety of agents including cyclophosphamide, methotrexate, nitrogen mustard, CCNU, and hydroxyurea did not improve survival.5'6 Recent studies have indicated that certain platinum-based regimens are more effective in non-small cell lung cancer than the chemotherapy used in these previous adjuvant studies. 7-9 In 1977 
MATERIALS AND METHODS

Eligibility
Patients were required to undergo a complete resection of the tumor, and specimens from the subcarinal, paratracheal, hilar, and bronchopulmonary lymph nodes areas were required for pathologic staging (Fig 1) . Patients were randomized within 14 days of surgery to receive either chemotherapy or immunotherapy. A permuted block randomization was used within strata, and treatment allocations were obtained by calling the central randomization desk in Potomac, Md, where eligibility was checked before assigning a treatment. Chemotherapy consisted of cyclophosphamide, 400 mg/m2n; doxorubicin, 40 mg/mi2; and cisplatin, 40 mg/m2 (CAP). This was administered monthly for 6 months beginning 20 to 30 days after surgery. Those randomized to receive immunotherapy received an intrapleural injection of 107 BCG (Tice) organisms in the chest tube in lobectomy patients or by thoracentesis in patients with pneumonectomy. The BCG was administered within 14 days of surgery and was obtained from the Chicago Research Institute. In addition, 300 mg isoniazid was administered daily for 12 weeks beginning 14 days after surgery. Levamisole, 2.5 mg/kg, was administered orally for 3 consecutive days every other week for 18 months. Follow-up examinations were scheduled monthly for 6 months, then quarterly for 6 months and semiannually thereafter. Chest radiographs, alkaline phosphatase, and liver function tests were among the required laboratory examinations.
Statistical Methods
The Pearson x2 was used for contingency table analyses with
Yates continuity correction in the case of 2X2 tables.10 A two-tailed test or trends in proportions was computed as per
Mantel with equally spaced scores.11 Survival curves were estimated as in Kaplan and Meier,12 and two sided significance tests were based on log rank statistics as given by Mantel, but without a continuity correction13 significance tests were also carried out with the modified Gehan test. 4 Adjusted survival analyses for stratification variables and for other important covariates were obtained from the Cox model'5 or from a stratified log rank score statistic. Variables were screened for prognostic value for recurrence with a score scatistic based on the proportional hazards model with stratification variable and for other important covariates were obtained from the Cox model'5 or from a stratified log rank score statistic. Variables were screened for prognostic value for recurrence with a score statistic based on the proportional hazards model with stratification for treatment. Survival and disease-free intervals were measured from the date of randomization. The abbreviation NS denotes a significance level >0.05, and two-sided tests were used.
Study Population
As of February 1988, 141 patients had been randomized into this study. A final pathology review by the Pathology Reference Center was completed in all but ten of these cases. Eleven patients were found to be ineligible. Eight patients were determined to have ineligible histology, one had microscopic involvement of the highest mediastinal lymph nodes, another patient died 6 days after randomization and before treatment, and a final patient had metastases proven within 1 week of randomization. Our analysis, therefore, focused on the remaining patients. Of these 130 patients, 23 patients did not receive the assigned treatment. Eight patients refused chemotherapy, and two patients refused BCG treatment after randomization. In addition, 13 eligible patients failed to receive the assigned treatment for other reasons. To avoid selection bias in the analysis that can arise by comparing only patients who received the assigned treatment, we performed our analysis on all of the 130 eligible patients including the 23 patients who did not receive the assigned treatment. The mean observation period for these 130 patients through February 1988, was 2.4 years, and the mean time since randomization was 7.5 years.
RESULTS
Treatment Balance
No statistically significant treatment imbalances were noted for the stratification factors or for other baseline covariates, including nodal status, performance status, race, gender, or history of heart disease. However, 16% of the immunotherapy patients had T3 tumors compared with 10% of the chemotherapy patients (trend test, p=0.024), whereas 60% of the chemotherapy patients were > age 60 compared with only 41% of the immunotherapy group (p=0.053). These two imbalances tend to cancel out. In addition, statistical adjustment for these factors did not change the results appreciably. Toxicity
Previously reported side effects associated with CAP chemotherapy were observed, including primarily gastrointestinal (87%) and hematologic toxicity (48%) as well as alopecia. Toxicity was classified as mild, moderate, or severe based on the Eastern Cooperative Oncology Group toxicity criteria. 6 In the chemotherapy group, there were five patients with severe hematologic toxicity, ten with moderate, and nine with mild. All but seven chemotherapy patients had gastrointestinal toxicity, but it should be noted that serotonin-antagonist antiemetics were not available during this trial. There were no fatalities attributed to the chemotherapy. Toxicity in the immunotherapy treatment group was mild and consistent with previous findings. ' (Fig 1) , and the treatment difference is statistically significant (log rank analysis p=0.032 and Gehan analysis p=0.003). Analysis of all deaths shows that the median survival is also about 7 months longer with CAP therapy (log rank p=0.113 and Gehan p=0.047) (Fig 2) . 
